
Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
561.480
Open
538.500
VWAP
553.24
Vol
657.97K
Mkt Cap
34.21B
Low
535.500
Amount
364.01M
EV/EBITDA(TTM)
140.37
Total Shares
59.43M
EV
30.72B
EV/OCF(TTM)
--
P/S(TTM)
13.92
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
1.04B
+37.64%
4.280
+477.54%
954.88M
+61.91%
3.594
+158.18%
876.33M
+79.17%
3.039
+575.76%
Estimates Revision
The market is revising Upward the revenue expectations for argenx SE (ARGX) for FY2025, with the revenue forecasts being adjusted by 8.95% over the past three months. During the same period, the stock price has changed by -13.89%.
Revenue Estimates for FY2025
Revise Upward

+8.95%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+11.05%
In Past 3 Month
Stock Price
Go Down

-13.89%
In Past 3 Month
21 Analyst Rating

34.20% Upside
Wall Street analysts forecast ARGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARGX is 752.74 USD with a low forecast of 620.00 USD and a high forecast of 1100 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Buy
2 Hold
0 Sell
Strong Buy

34.20% Upside
Current: 560.900

Low
620.00
Averages
752.74
High
1100

34.20% Upside
Current: 560.900

Low
620.00
Averages
752.74
High
1100
Citigroup
Samantha Semenkow
Strong Buy
Maintains
$796 → $803
2025-05-09
New
Reason
Citigroup
Samantha Semenkow
Price Target
$796 → $803
2025-05-09
New
Maintains
Strong Buy
Reason
Guggenheim
Yatin Suneja
Strong Buy
Maintains
$1,100 → $1,065
2025-05-09
New
Reason
Guggenheim
Yatin Suneja
Price Target
$1,100 → $1,065
2025-05-09
New
Maintains
Strong Buy
Reason
Oppenheimer
Leland Gershell
Buy
Maintains
$704 → $708
2025-05-09
New
Reason
Oppenheimer
Leland Gershell
Price Target
$704 → $708
2025-05-09
New
Maintains
Buy
Reason
Citigroup
Samantha Semenkow
Strong Buy
Maintains
$681 → $796
2025-04-17
Reason
Citigroup
Samantha Semenkow
Price Target
$681 → $796
2025-04-17
Maintains
Strong Buy
Reason
Wedbush
David Nierengarten
Buy
Reiterates
$715
2025-04-16
Reason
Wedbush
David Nierengarten
Price Target
$715
2025-04-16
Reiterates
Buy
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$720
2025-04-11
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$720
2025-04-11
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for argenx SE (ARGX.O) is 37.78, compared to its 5-year average forward P/E of -79.54. For a more detailed relative valuation and DCF analysis to assess argenx SE 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-79.54
Current PE
37.78
Overvalued PE
134.22
Undervalued PE
-293.31
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-14.38
Current EV/EBITDA
30.43
Overvalued EV/EBITDA
86.10
Undervalued EV/EBITDA
-114.87
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
38.76
Current PS
8.80
Overvalued PS
70.38
Undervalued PS
7.13
Financials
Annual
Quarterly
FY2025Q1
YoY :
+97.18%
790.68M
Total Revenue
FY2025Q1
YoY :
-254.15%
141.25M
Operating Profit
FY2025Q1
YoY :
-375.13%
169.47M
Net Income after Tax
FY2025Q1
YoY :
-348.08%
2.58
EPS - Diluted
FY2025Q1
YoY :
+0.62%
89.78
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
YoY :
-239.52%
21.43
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
332.0K
Volume
5
6-9
Months
0.0
Volume
0
0-12
Months
284.0K
Volume
12
Bought
0-3
0
0.0
Volume
Months
3-6
6
118.6K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
12
1.3M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ARGX News & Events
Events Timeline
2025-05-09 (ET)
2025-05-09
09:43:08
Argenx selloff a buying opportunity, says TD Cowen

2025-05-08 (ET)
2025-05-08
05:42:27
Argenx reports Q1 EPS $2.58, consensus $2.75

2025-04-28 (ET)
2025-04-28
05:20:14
Argenx announces CHMP opinion recommending approval of Vyvgart 1000mg

Sign Up For More Events
Sign Up For More Events
News
4.0
05-09BenzingaOppenheimer Maintains Outperform on argenx, Raises Price Target to $708
4.0
05-09BenzingaGuggenheim Maintains Buy on argenx, Lowers Price Target to $1065
4.5
05-08BenzingaCrude Oil Gains Over 2%; US Foods Posts Downbeat Earnings
Sign Up For More News
People Also Watch

CRDF
Cardiff Oncology Inc
2.750
USD
+3.38%

CATX
Perspective Therapeutics Inc
2.510
USD
+6.81%

ARAY
Accuray Inc
1.660
USD
+9.93%

FUND
Sprott Focus Trust Inc
7.270
USD
+1.68%

SRG
Seritage Growth Properties
2.990
USD
+1.01%

ABEO
Abeona Therapeutics Inc
5.600
USD
+6.26%

ELLO
Ellomay Capital Ltd
15.900
USD
+1.34%

FLYX
Flyexclusive Inc
3.050
USD
+2.01%

RDCM
Radcom Ltd
12.380
USD
-1.82%

CIA
Citizens Inc
3.990
USD
+5.56%
FAQ

What is argenx SE (ARGX) stock price today?
The current price of ARGX is 560.9 USD — it has increased 2.05 % in the last trading day.

What is argenx SE (ARGX)'s business?

What is the price predicton of ARGX Stock?

What is argenx SE (ARGX)'s revenue for the last quarter?

What is argenx SE (ARGX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for argenx SE (ARGX)'s fundamentals?

How many employees does argenx SE (ARGX). have?
